nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftazidime—SLC22A5—Organic cation transport—SLC22A18—breast cancer	0.0103	0.115	CbGpPWpGaD
Ceftazidime—SLC22A5—Organic cation/anion/zwitterion transport—SLC22A18—breast cancer	0.00695	0.0778	CbGpPWpGaD
Ceftazidime—SLC22A6—Organic cation/anion/zwitterion transport—SLC22A18—breast cancer	0.00525	0.0587	CbGpPWpGaD
Ceftazidime—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC4A7—breast cancer	0.00205	0.0229	CbGpPWpGaD
Ceftazidime—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC4A7—breast cancer	0.0019	0.0213	CbGpPWpGaD
Ceftazidime—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A10—breast cancer	0.00184	0.0206	CbGpPWpGaD
Ceftazidime—SLC15A2—mammary gland—breast cancer	0.00177	0.0952	CbGeAlD
Ceftazidime—SLC15A1—epithelium—breast cancer	0.00158	0.0848	CbGeAlD
Ceftazidime—SLC22A5—mammary gland—breast cancer	0.00154	0.0828	CbGeAlD
Ceftazidime—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A7—breast cancer	0.00152	0.017	CbGpPWpGaD
Ceftazidime—SLC15A1—endometrium—breast cancer	0.00141	0.0761	CbGeAlD
Ceftazidime—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A18—breast cancer	0.00139	0.0156	CbGpPWpGaD
Ceftazidime—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A10—breast cancer	0.00139	0.0155	CbGpPWpGaD
Ceftazidime—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A5—breast cancer	0.00134	0.015	CbGpPWpGaD
Ceftazidime—SLC22A5—nipple—breast cancer	0.00127	0.0685	CbGeAlD
Ceftazidime—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A6—breast cancer	0.00115	0.0129	CbGpPWpGaD
Ceftazidime—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A7—breast cancer	0.00115	0.0129	CbGpPWpGaD
Ceftazidime—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC5A5—breast cancer	0.00105	0.0118	CbGpPWpGaD
Ceftazidime—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A18—breast cancer	0.00105	0.0118	CbGpPWpGaD
Ceftazidime—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A5—breast cancer	0.00101	0.0113	CbGpPWpGaD
Ceftazidime—SLC15A2—SLC-mediated transmembrane transport—SLC28A1—breast cancer	0.001	0.0112	CbGpPWpGaD
Ceftazidime—SLC15A1—endocrine gland—breast cancer	0.000992	0.0533	CbGeAlD
Ceftazidime—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC5A5—breast cancer	0.000977	0.0109	CbGpPWpGaD
Ceftazidime—SLC15A1—SLC-mediated transmembrane transport—SLC28A1—breast cancer	0.000928	0.0104	CbGpPWpGaD
Ceftazidime—SLC15A2—SLC-mediated transmembrane transport—SLC4A7—breast cancer	0.000915	0.0102	CbGpPWpGaD
Ceftazidime—SLC15A2—SLC-mediated transmembrane transport—SLC2A10—breast cancer	0.000915	0.0102	CbGpPWpGaD
Ceftazidime—SLC22A5—SLC-mediated transmembrane transport—SLC28A1—breast cancer	0.000913	0.0102	CbGpPWpGaD
Ceftazidime—SLC15A2—endometrium—breast cancer	0.000884	0.0475	CbGeAlD
Ceftazidime—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A6—breast cancer	0.000871	0.00974	CbGpPWpGaD
Ceftazidime—SLC15A1—SLC-mediated transmembrane transport—SLC2A10—breast cancer	0.000849	0.0095	CbGpPWpGaD
Ceftazidime—SLC15A1—SLC-mediated transmembrane transport—SLC4A7—breast cancer	0.000849	0.0095	CbGpPWpGaD
Ceftazidime—SLC22A5—SLC-mediated transmembrane transport—SLC2A10—breast cancer	0.000835	0.00934	CbGpPWpGaD
Ceftazidime—SLC22A5—SLC-mediated transmembrane transport—SLC4A7—breast cancer	0.000835	0.00934	CbGpPWpGaD
Ceftazidime—SLC22A5—skin of body—breast cancer	0.000816	0.0439	CbGeAlD
Ceftazidime—SLC15A2—pituitary gland—breast cancer	0.0008	0.043	CbGeAlD
Ceftazidime—SLC22A5—endometrium—breast cancer	0.000769	0.0414	CbGeAlD
Ceftazidime—SLC15A2—SLC-mediated transmembrane transport—SLC39A7—breast cancer	0.000758	0.00848	CbGpPWpGaD
Ceftazidime—SLC15A2—female reproductive system—breast cancer	0.000733	0.0394	CbGeAlD
Ceftazidime—SLC15A2—adrenal gland—breast cancer	0.000715	0.0384	CbGeAlD
Ceftazidime—SLC15A1—SLC-mediated transmembrane transport—SLC39A7—breast cancer	0.000704	0.00787	CbGpPWpGaD
Ceftazidime—SLC22A5—pituitary gland—breast cancer	0.000696	0.0374	CbGeAlD
Ceftazidime—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A2—breast cancer	0.000694	0.00776	CbGpPWpGaD
Ceftazidime—SLC15A2—SLC-mediated transmembrane transport—SLC22A18—breast cancer	0.000693	0.00775	CbGpPWpGaD
Ceftazidime—SLC22A5—adipose tissue—breast cancer	0.000693	0.0373	CbGeAlD
Ceftazidime—SLC22A5—SLC-mediated transmembrane transport—SLC39A7—breast cancer	0.000692	0.00774	CbGpPWpGaD
Ceftazidime—SLC22A6—SLC-mediated transmembrane transport—SLC28A1—breast cancer	0.000689	0.00771	CbGpPWpGaD
Ceftazidime—SLC15A2—SLC-mediated transmembrane transport—SLC2A5—breast cancer	0.000667	0.00746	CbGpPWpGaD
Ceftazidime—SLC15A2—SLC-mediated transmembrane transport—SLCO1B1—breast cancer	0.000667	0.00746	CbGpPWpGaD
Ceftazidime—SLC15A2—female gonad—breast cancer	0.000667	0.0358	CbGeAlD
Ceftazidime—SLC15A1—SLC-mediated transmembrane transport—SLC22A18—breast cancer	0.000643	0.0072	CbGpPWpGaD
Ceftazidime—SLC22A5—female reproductive system—breast cancer	0.000637	0.0343	CbGeAlD
Ceftazidime—SLC22A5—SLC-mediated transmembrane transport—SLC22A18—breast cancer	0.000633	0.00708	CbGpPWpGaD
Ceftazidime—SLC22A6—SLC-mediated transmembrane transport—SLC2A10—breast cancer	0.00063	0.00705	CbGpPWpGaD
Ceftazidime—SLC22A6—SLC-mediated transmembrane transport—SLC4A7—breast cancer	0.00063	0.00705	CbGpPWpGaD
Ceftazidime—SLC22A5—adrenal gland—breast cancer	0.000622	0.0334	CbGeAlD
Ceftazidime—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—breast cancer	0.00062	0.00694	CbGpPWpGaD
Ceftazidime—SLC15A2—endocrine gland—breast cancer	0.00062	0.0333	CbGeAlD
Ceftazidime—SLC15A1—SLC-mediated transmembrane transport—SLCO1B1—breast cancer	0.000619	0.00693	CbGpPWpGaD
Ceftazidime—SLC15A1—SLC-mediated transmembrane transport—SLC2A5—breast cancer	0.000619	0.00693	CbGpPWpGaD
Ceftazidime—SLC22A5—SLC-mediated transmembrane transport—SLCO1B1—breast cancer	0.000609	0.00681	CbGpPWpGaD
Ceftazidime—SLC22A5—SLC-mediated transmembrane transport—SLC2A5—breast cancer	0.000609	0.00681	CbGpPWpGaD
Ceftazidime—SLC22A5—female gonad—breast cancer	0.00058	0.0312	CbGeAlD
Ceftazidime—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—breast cancer	0.000576	0.00644	CbGpPWpGaD
Ceftazidime—SLC15A2—SLC-mediated transmembrane transport—SLC39A6—breast cancer	0.000575	0.00643	CbGpPWpGaD
Ceftazidime—SLC15A1—SLC-mediated transmembrane transport—SLC39A6—breast cancer	0.000533	0.00596	CbGpPWpGaD
Ceftazidime—SLC22A5—SLC-mediated transmembrane transport—SLC39A6—breast cancer	0.000524	0.00586	CbGpPWpGaD
Ceftazidime—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A2—breast cancer	0.000524	0.00586	CbGpPWpGaD
Ceftazidime—SLC22A6—SLC-mediated transmembrane transport—SLC39A7—breast cancer	0.000522	0.00584	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—SLC28A1—breast cancer	0.000508	0.00569	CbGpPWpGaD
Ceftazidime—SLC22A6—SLC-mediated transmembrane transport—SLC22A18—breast cancer	0.000478	0.00534	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—SLC28A1—breast cancer	0.000472	0.00528	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—SLC2A10—breast cancer	0.000465	0.0052	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—SLC4A7—breast cancer	0.000465	0.0052	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—SLC28A1—breast cancer	0.000464	0.00519	CbGpPWpGaD
Ceftazidime—SLC22A6—SLC-mediated transmembrane transport—SLC2A5—breast cancer	0.00046	0.00514	CbGpPWpGaD
Ceftazidime—SLC22A6—SLC-mediated transmembrane transport—SLCO1B1—breast cancer	0.00046	0.00514	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—SLC2A10—breast cancer	0.000431	0.00483	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—SLC4A7—breast cancer	0.000431	0.00483	CbGpPWpGaD
Ceftazidime—SLC15A2—lymph node—breast cancer	0.000429	0.023	CbGeAlD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—SLC4A7—breast cancer	0.000424	0.00475	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—SLC2A10—breast cancer	0.000424	0.00475	CbGpPWpGaD
Ceftazidime—Pruritus—Thiotepa—breast cancer	0.000416	0.000466	CcSEcCtD
Ceftazidime—Pain—Fluorouracil—breast cancer	0.000416	0.000466	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Irinotecan—breast cancer	0.000415	0.000465	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Mitoxantrone—breast cancer	0.000415	0.000465	CcSEcCtD
Ceftazidime—Anaphylactic shock—Paclitaxel—breast cancer	0.000414	0.000464	CcSEcCtD
Ceftazidime—Eosinophilia—Epirubicin—breast cancer	0.000412	0.000462	CcSEcCtD
Ceftazidime—Nausea—Goserelin—breast cancer	0.000408	0.000458	CcSEcCtD
Ceftazidime—Dysgeusia—Capecitabine—breast cancer	0.000408	0.000457	CcSEcCtD
Ceftazidime—Dizziness—Vinorelbine—breast cancer	0.000407	0.000456	CcSEcCtD
Ceftazidime—Nervous system disorder—Paclitaxel—breast cancer	0.000406	0.000455	CcSEcCtD
Ceftazidime—Thrombocytopenia—Paclitaxel—breast cancer	0.000405	0.000454	CcSEcCtD
Ceftazidime—Urticaria—Mitoxantrone—breast cancer	0.000403	0.000452	CcSEcCtD
Ceftazidime—Diarrhoea—Thiotepa—breast cancer	0.000402	0.000451	CcSEcCtD
Ceftazidime—Skin disorder—Paclitaxel—breast cancer	0.000402	0.000451	CcSEcCtD
Ceftazidime—Abdominal pain—Mitoxantrone—breast cancer	0.000401	0.00045	CcSEcCtD
Ceftazidime—Body temperature increased—Mitoxantrone—breast cancer	0.000401	0.00045	CcSEcCtD
Ceftazidime—Body temperature increased—Irinotecan—breast cancer	0.000401	0.00045	CcSEcCtD
Ceftazidime—Abdominal pain—Irinotecan—breast cancer	0.000401	0.00045	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Doxorubicin—breast cancer	0.000401	0.00045	CcSEcCtD
Ceftazidime—Infestation—Methotrexate—breast cancer	0.000397	0.000445	CcSEcCtD
Ceftazidime—Infestation NOS—Methotrexate—breast cancer	0.000397	0.000445	CcSEcCtD
Ceftazidime—SLC22A6—SLC-mediated transmembrane transport—SLC39A6—breast cancer	0.000396	0.00443	CbGpPWpGaD
Ceftazidime—Pancytopenia—Epirubicin—breast cancer	0.000395	0.000443	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Methotrexate—breast cancer	0.000393	0.000441	CcSEcCtD
Ceftazidime—Vision blurred—Capecitabine—breast cancer	0.000392	0.00044	CcSEcCtD
Ceftazidime—Vomiting—Vinorelbine—breast cancer	0.000391	0.000439	CcSEcCtD
Ceftazidime—Body temperature increased—Gemcitabine—breast cancer	0.000391	0.000438	CcSEcCtD
Ceftazidime—Tremor—Capecitabine—breast cancer	0.00039	0.000437	CcSEcCtD
Ceftazidime—Renal failure—Methotrexate—breast cancer	0.00039	0.000437	CcSEcCtD
Ceftazidime—Neutropenia—Epirubicin—breast cancer	0.000389	0.000436	CcSEcCtD
Ceftazidime—Dizziness—Thiotepa—breast cancer	0.000389	0.000436	CcSEcCtD
Ceftazidime—Rash—Vinorelbine—breast cancer	0.000388	0.000435	CcSEcCtD
Ceftazidime—Dermatitis—Vinorelbine—breast cancer	0.000388	0.000435	CcSEcCtD
Ceftazidime—Hypotension—Paclitaxel—breast cancer	0.000387	0.000434	CcSEcCtD
Ceftazidime—Urticaria—Fluorouracil—breast cancer	0.000386	0.000433	CcSEcCtD
Ceftazidime—Headache—Vinorelbine—breast cancer	0.000386	0.000432	CcSEcCtD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—SLC39A7—breast cancer	0.000385	0.00431	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—COX11—breast cancer	0.000385	0.00431	CbGpPWpGaD
Ceftazidime—Leukopenia—Docetaxel—breast cancer	0.000385	0.000431	CcSEcCtD
Ceftazidime—Body temperature increased—Fluorouracil—breast cancer	0.000384	0.000431	CcSEcCtD
Ceftazidime—Eosinophilia—Doxorubicin—breast cancer	0.000381	0.000427	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Methotrexate—breast cancer	0.000375	0.00042	CcSEcCtD
Ceftazidime—Hypersensitivity—Irinotecan—breast cancer	0.000374	0.000419	CcSEcCtD
Ceftazidime—Hypersensitivity—Mitoxantrone—breast cancer	0.000374	0.000419	CcSEcCtD
Ceftazidime—Vomiting—Thiotepa—breast cancer	0.000374	0.000419	CcSEcCtD
Ceftazidime—SLC22A5—lymph node—breast cancer	0.000373	0.02	CbGeAlD
Ceftazidime—Leukopenia—Capecitabine—breast cancer	0.000373	0.000418	CcSEcCtD
Ceftazidime—Convulsion—Docetaxel—breast cancer	0.000372	0.000418	CcSEcCtD
Ceftazidime—Paraesthesia—Paclitaxel—breast cancer	0.000372	0.000417	CcSEcCtD
Ceftazidime—Infestation NOS—Epirubicin—breast cancer	0.000371	0.000416	CcSEcCtD
Ceftazidime—Infestation—Epirubicin—breast cancer	0.000371	0.000416	CcSEcCtD
Ceftazidime—Rash—Thiotepa—breast cancer	0.000371	0.000415	CcSEcCtD
Ceftazidime—Dermatitis—Thiotepa—breast cancer	0.00037	0.000415	CcSEcCtD
Ceftazidime—Agranulocytosis—Methotrexate—breast cancer	0.00037	0.000415	CcSEcCtD
Ceftazidime—Headache—Thiotepa—breast cancer	0.000368	0.000413	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Epirubicin—breast cancer	0.000368	0.000412	CcSEcCtD
Ceftazidime—Pancytopenia—Doxorubicin—breast cancer	0.000366	0.00041	CcSEcCtD
Ceftazidime—Nausea—Vinorelbine—breast cancer	0.000366	0.00041	CcSEcCtD
Ceftazidime—Renal failure—Epirubicin—breast cancer	0.000365	0.000409	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	0.000363	0.000407	CcSEcCtD
Ceftazidime—Jaundice—Epirubicin—breast cancer	0.000362	0.000405	CcSEcCtD
Ceftazidime—Neutropenia—Doxorubicin—breast cancer	0.00036	0.000404	CcSEcCtD
Ceftazidime—Hypersensitivity—Fluorouracil—breast cancer	0.000358	0.000402	CcSEcCtD
Ceftazidime—Haemoglobin—Methotrexate—breast cancer	0.000358	0.000401	CcSEcCtD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—SLC39A7—breast cancer	0.000358	0.004	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—COX11—breast cancer	0.000358	0.004	CbGpPWpGaD
Ceftazidime—Gastrointestinal disorder—Paclitaxel—breast cancer	0.000357	0.000401	CcSEcCtD
Ceftazidime—Haemorrhage—Methotrexate—breast cancer	0.000356	0.000399	CcSEcCtD
Ceftazidime—Pain—Paclitaxel—breast cancer	0.000354	0.000397	CcSEcCtD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—SLC22A18—breast cancer	0.000352	0.00394	CbGpPWpGaD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	0.000352	0.000395	CcSEcCtD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—SLC39A7—breast cancer	0.000352	0.00393	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—COX11—breast cancer	0.000352	0.00393	CbGpPWpGaD
Ceftazidime—Hepatobiliary disease—Epirubicin—breast cancer	0.000351	0.000393	CcSEcCtD
Ceftazidime—Anaphylactic shock—Docetaxel—breast cancer	0.000351	0.000393	CcSEcCtD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—SLC28A1—breast cancer	0.00035	0.00392	CbGpPWpGaD
Ceftazidime—Pruritus—Gemcitabine—breast cancer	0.00035	0.000392	CcSEcCtD
Ceftazidime—Nausea—Thiotepa—breast cancer	0.000349	0.000391	CcSEcCtD
Ceftazidime—Diarrhoea—Irinotecan—breast cancer	0.000347	0.000389	CcSEcCtD
Ceftazidime—Diarrhoea—Mitoxantrone—breast cancer	0.000347	0.000389	CcSEcCtD
Ceftazidime—Agranulocytosis—Epirubicin—breast cancer	0.000346	0.000388	CcSEcCtD
Ceftazidime—SLC15A2—SLC-mediated transmembrane transport—SLC2A2—breast cancer	0.000346	0.00387	CbGpPWpGaD
Ceftazidime—Nervous system disorder—Docetaxel—breast cancer	0.000344	0.000386	CcSEcCtD
Ceftazidime—Pruritus—Fluorouracil—breast cancer	0.000344	0.000386	CcSEcCtD
Ceftazidime—Thrombocytopenia—Docetaxel—breast cancer	0.000344	0.000385	CcSEcCtD
Ceftazidime—Infestation NOS—Doxorubicin—breast cancer	0.000343	0.000385	CcSEcCtD
Ceftazidime—Infestation—Doxorubicin—breast cancer	0.000343	0.000385	CcSEcCtD
Ceftazidime—Skin disorder—Docetaxel—breast cancer	0.000341	0.000382	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Doxorubicin—breast cancer	0.00034	0.000382	CcSEcCtD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—SLCO1B1—breast cancer	0.000339	0.00379	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—SLC2A5—breast cancer	0.000339	0.00379	CbGpPWpGaD
Ceftazidime—Gastrointestinal pain—Paclitaxel—breast cancer	0.000338	0.000379	CcSEcCtD
Ceftazidime—Diarrhoea—Gemcitabine—breast cancer	0.000338	0.000379	CcSEcCtD
Ceftazidime—Renal failure—Doxorubicin—breast cancer	0.000337	0.000378	CcSEcCtD
Ceftazidime—Erythema multiforme—Methotrexate—breast cancer	0.000337	0.000377	CcSEcCtD
Ceftazidime—Dizziness—Irinotecan—breast cancer	0.000336	0.000376	CcSEcCtD
Ceftazidime—Haemoglobin—Epirubicin—breast cancer	0.000335	0.000375	CcSEcCtD
Ceftazidime—Jaundice—Doxorubicin—breast cancer	0.000335	0.000375	CcSEcCtD
Ceftazidime—Nervous system disorder—Capecitabine—breast cancer	0.000333	0.000373	CcSEcCtD
Ceftazidime—Haemorrhage—Epirubicin—breast cancer	0.000333	0.000373	CcSEcCtD
Ceftazidime—Diarrhoea—Fluorouracil—breast cancer	0.000333	0.000373	CcSEcCtD
Ceftazidime—Thrombocytopenia—Capecitabine—breast cancer	0.000333	0.000373	CcSEcCtD
Ceftazidime—Skin disorder—Capecitabine—breast cancer	0.00033	0.00037	CcSEcCtD
Ceftazidime—Urticaria—Paclitaxel—breast cancer	0.000329	0.000369	CcSEcCtD
Ceftazidime—Hypotension—Docetaxel—breast cancer	0.000328	0.000368	CcSEcCtD
Ceftazidime—Body temperature increased—Paclitaxel—breast cancer	0.000327	0.000367	CcSEcCtD
Ceftazidime—Abdominal pain—Paclitaxel—breast cancer	0.000327	0.000367	CcSEcCtD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—SLC22A18—breast cancer	0.000327	0.00366	CbGpPWpGaD
Ceftazidime—Hepatobiliary disease—Doxorubicin—breast cancer	0.000325	0.000364	CcSEcCtD
Ceftazidime—Angiopathy—Methotrexate—breast cancer	0.000323	0.000362	CcSEcCtD
Ceftazidime—Vomiting—Irinotecan—breast cancer	0.000323	0.000362	CcSEcCtD
Ceftazidime—Vomiting—Mitoxantrone—breast cancer	0.000323	0.000362	CcSEcCtD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—SLC22A18—breast cancer	0.000322	0.0036	CbGpPWpGaD
Ceftazidime—Immune system disorder—Methotrexate—breast cancer	0.000322	0.00036	CcSEcCtD
Ceftazidime—Dizziness—Fluorouracil—breast cancer	0.000321	0.00036	CcSEcCtD
Ceftazidime—SLC15A1—SLC-mediated transmembrane transport—SLC2A2—breast cancer	0.000321	0.00359	CbGpPWpGaD
Ceftazidime—Agranulocytosis—Doxorubicin—breast cancer	0.00032	0.000359	CcSEcCtD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—SLC2A10—breast cancer	0.00032	0.00358	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—SLC4A7—breast cancer	0.00032	0.00358	CbGpPWpGaD
Ceftazidime—Rash—Irinotecan—breast cancer	0.00032	0.000359	CcSEcCtD
Ceftazidime—Rash—Mitoxantrone—breast cancer	0.00032	0.000359	CcSEcCtD
Ceftazidime—Dermatitis—Irinotecan—breast cancer	0.00032	0.000358	CcSEcCtD
Ceftazidime—Dermatitis—Mitoxantrone—breast cancer	0.00032	0.000358	CcSEcCtD
Ceftazidime—Headache—Irinotecan—breast cancer	0.000318	0.000356	CcSEcCtD
Ceftazidime—Headache—Mitoxantrone—breast cancer	0.000318	0.000356	CcSEcCtD
Ceftazidime—Hypotension—Capecitabine—breast cancer	0.000317	0.000356	CcSEcCtD
Ceftazidime—SLC22A5—SLC-mediated transmembrane transport—SLC2A2—breast cancer	0.000315	0.00353	CbGpPWpGaD
Ceftazidime—Paraesthesia—Docetaxel—breast cancer	0.000315	0.000353	CcSEcCtD
Ceftazidime—Erythema multiforme—Epirubicin—breast cancer	0.000315	0.000353	CcSEcCtD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—SLC2A5—breast cancer	0.000315	0.00352	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—SLCO1B1—breast cancer	0.000315	0.00352	CbGpPWpGaD
Ceftazidime—Vomiting—Gemcitabine—breast cancer	0.000314	0.000352	CcSEcCtD
Ceftazidime—Rash—Gemcitabine—breast cancer	0.000312	0.000349	CcSEcCtD
Ceftazidime—Dermatitis—Gemcitabine—breast cancer	0.000311	0.000349	CcSEcCtD
Ceftazidime—Haemoglobin—Doxorubicin—breast cancer	0.00031	0.000347	CcSEcCtD
Ceftazidime—Headache—Gemcitabine—breast cancer	0.00031	0.000347	CcSEcCtD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—SLC2A5—breast cancer	0.00031	0.00346	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—SLCO1B1—breast cancer	0.00031	0.00346	CbGpPWpGaD
Ceftazidime—Flushing—Epirubicin—breast cancer	0.000309	0.000347	CcSEcCtD
Ceftazidime—Vomiting—Fluorouracil—breast cancer	0.000309	0.000347	CcSEcCtD
Ceftazidime—Haemorrhage—Doxorubicin—breast cancer	0.000308	0.000346	CcSEcCtD
Ceftazidime—Rash—Fluorouracil—breast cancer	0.000307	0.000344	CcSEcCtD
Ceftazidime—Dermatitis—Fluorouracil—breast cancer	0.000306	0.000343	CcSEcCtD
Ceftazidime—Paraesthesia—Capecitabine—breast cancer	0.000305	0.000342	CcSEcCtD
Ceftazidime—Hypersensitivity—Paclitaxel—breast cancer	0.000305	0.000342	CcSEcCtD
Ceftazidime—Headache—Fluorouracil—breast cancer	0.000305	0.000341	CcSEcCtD
Ceftazidime—Dysgeusia—Methotrexate—breast cancer	0.000303	0.00034	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Docetaxel—breast cancer	0.000303	0.00034	CcSEcCtD
Ceftazidime—Angiopathy—Epirubicin—breast cancer	0.000302	0.000339	CcSEcCtD
Ceftazidime—Nausea—Mitoxantrone—breast cancer	0.000301	0.000338	CcSEcCtD
Ceftazidime—Nausea—Irinotecan—breast cancer	0.000301	0.000338	CcSEcCtD
Ceftazidime—Immune system disorder—Epirubicin—breast cancer	0.000301	0.000337	CcSEcCtD
Ceftazidime—Pain—Docetaxel—breast cancer	0.0003	0.000336	CcSEcCtD
Ceftazidime—Nausea—Gemcitabine—breast cancer	0.000294	0.000329	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Capecitabine—breast cancer	0.000293	0.000329	CcSEcCtD
Ceftazidime—Pruritus—Paclitaxel—breast cancer	0.000293	0.000328	CcSEcCtD
Ceftazidime—Vision blurred—Methotrexate—breast cancer	0.000292	0.000327	CcSEcCtD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—SLC39A6—breast cancer	0.000292	0.00327	CbGpPWpGaD
Ceftazidime—Erythema multiforme—Doxorubicin—breast cancer	0.000291	0.000327	CcSEcCtD
Ceftazidime—Pain—Capecitabine—breast cancer	0.00029	0.000326	CcSEcCtD
Ceftazidime—Nausea—Fluorouracil—breast cancer	0.000289	0.000324	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Docetaxel—breast cancer	0.000287	0.000322	CcSEcCtD
Ceftazidime—Flushing—Doxorubicin—breast cancer	0.000286	0.000321	CcSEcCtD
Ceftazidime—Dysgeusia—Epirubicin—breast cancer	0.000284	0.000318	CcSEcCtD
Ceftazidime—Diarrhoea—Paclitaxel—breast cancer	0.000283	0.000318	CcSEcCtD
Ceftazidime—Angiopathy—Doxorubicin—breast cancer	0.00028	0.000313	CcSEcCtD
Ceftazidime—Immune system disorder—Doxorubicin—breast cancer	0.000278	0.000312	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Capecitabine—breast cancer	0.000278	0.000311	CcSEcCtD
Ceftazidime—Body temperature increased—Docetaxel—breast cancer	0.000277	0.000311	CcSEcCtD
Ceftazidime—Abdominal pain—Docetaxel—breast cancer	0.000277	0.000311	CcSEcCtD
Ceftazidime—Leukopenia—Methotrexate—breast cancer	0.000277	0.000311	CcSEcCtD
Ceftazidime—SLC15A2—SLC-mediated transmembrane transport—SLC5A5—breast cancer	0.000277	0.0031	CbGpPWpGaD
Ceftazidime—Dizziness—Paclitaxel—breast cancer	0.000274	0.000307	CcSEcCtD
Ceftazidime—Vision blurred—Epirubicin—breast cancer	0.000273	0.000306	CcSEcCtD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—SLC39A6—breast cancer	0.000271	0.00303	CbGpPWpGaD
Ceftazidime—Urticaria—Capecitabine—breast cancer	0.00027	0.000303	CcSEcCtD
Ceftazidime—Abdominal pain—Capecitabine—breast cancer	0.000269	0.000301	CcSEcCtD
Ceftazidime—Body temperature increased—Capecitabine—breast cancer	0.000269	0.000301	CcSEcCtD
Ceftazidime—Convulsion—Methotrexate—breast cancer	0.000268	0.000301	CcSEcCtD
Ceftazidime—SLC15A2—SLC-mediated transmembrane transport—SLC2A1—breast cancer	0.000268	0.00299	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—ATP7B—breast cancer	0.000267	0.00299	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—SLC39A6—breast cancer	0.000266	0.00298	CbGpPWpGaD
Ceftazidime—Agitation—Epirubicin—breast cancer	0.000266	0.000299	CcSEcCtD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—SLC39A7—breast cancer	0.000265	0.00297	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—COX11—breast cancer	0.000265	0.00297	CbGpPWpGaD
Ceftazidime—Vomiting—Paclitaxel—breast cancer	0.000263	0.000295	CcSEcCtD
Ceftazidime—Dysgeusia—Doxorubicin—breast cancer	0.000263	0.000295	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	0.000262	0.000294	CcSEcCtD
Ceftazidime—Rash—Paclitaxel—breast cancer	0.000261	0.000293	CcSEcCtD
Ceftazidime—Dermatitis—Paclitaxel—breast cancer	0.000261	0.000292	CcSEcCtD
Ceftazidime—Leukopenia—Epirubicin—breast cancer	0.00026	0.000291	CcSEcCtD
Ceftazidime—Headache—Paclitaxel—breast cancer	0.000259	0.000291	CcSEcCtD
Ceftazidime—Hypersensitivity—Docetaxel—breast cancer	0.000259	0.00029	CcSEcCtD
Ceftazidime—SLC15A1—SLC-mediated transmembrane transport—SLC5A5—breast cancer	0.000257	0.00288	CbGpPWpGaD
Ceftazidime—SLC22A5—SLC-mediated transmembrane transport—SLC5A5—breast cancer	0.000253	0.00283	CbGpPWpGaD
Ceftazidime—Anaphylactic shock—Methotrexate—breast cancer	0.000253	0.000284	CcSEcCtD
Ceftazidime—Vision blurred—Doxorubicin—breast cancer	0.000253	0.000283	CcSEcCtD
Ceftazidime—Convulsion—Epirubicin—breast cancer	0.000251	0.000282	CcSEcCtD
Ceftazidime—Hypersensitivity—Capecitabine—breast cancer	0.00025	0.000281	CcSEcCtD
Ceftazidime—SLC15A1—SLC-mediated transmembrane transport—SLC2A1—breast cancer	0.000248	0.00278	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—ABCC1—breast cancer	0.000248	0.00278	CbGpPWpGaD
Ceftazidime—Pruritus—Docetaxel—breast cancer	0.000248	0.000278	CcSEcCtD
Ceftazidime—Nervous system disorder—Methotrexate—breast cancer	0.000248	0.000278	CcSEcCtD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—ATP7B—breast cancer	0.000248	0.00277	CbGpPWpGaD
Ceftazidime—Thrombocytopenia—Methotrexate—breast cancer	0.000248	0.000278	CcSEcCtD
Ceftazidime—Agitation—Doxorubicin—breast cancer	0.000247	0.000276	CcSEcCtD
Ceftazidime—Nausea—Paclitaxel—breast cancer	0.000246	0.000276	CcSEcCtD
Ceftazidime—Skin disorder—Methotrexate—breast cancer	0.000246	0.000275	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	0.000245	0.000275	CcSEcCtD
Ceftazidime—SLC22A5—SLC-mediated transmembrane transport—SLC2A1—breast cancer	0.000244	0.00273	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—ATP7B—breast cancer	0.000244	0.00273	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—SLC22A18—breast cancer	0.000243	0.00271	CbGpPWpGaD
Ceftazidime—Pruritus—Capecitabine—breast cancer	0.00024	0.000269	CcSEcCtD
Ceftazidime—Leukopenia—Doxorubicin—breast cancer	0.00024	0.000269	CcSEcCtD
Ceftazidime—Diarrhoea—Docetaxel—breast cancer	0.00024	0.000269	CcSEcCtD
Ceftazidime—SLC22A6—SLC-mediated transmembrane transport—SLC2A2—breast cancer	0.000238	0.00266	CbGpPWpGaD
Ceftazidime—Anaphylactic shock—Epirubicin—breast cancer	0.000237	0.000265	CcSEcCtD
Ceftazidime—Hypotension—Methotrexate—breast cancer	0.000236	0.000265	CcSEcCtD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—SLC2A5—breast cancer	0.000234	0.00261	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—SLCO1B1—breast cancer	0.000234	0.00261	CbGpPWpGaD
Ceftazidime—Convulsion—Doxorubicin—breast cancer	0.000232	0.000261	CcSEcCtD
Ceftazidime—Diarrhoea—Capecitabine—breast cancer	0.000232	0.000261	CcSEcCtD
Ceftazidime—Nervous system disorder—Epirubicin—breast cancer	0.000232	0.00026	CcSEcCtD
Ceftazidime—Dizziness—Docetaxel—breast cancer	0.000232	0.00026	CcSEcCtD
Ceftazidime—Thrombocytopenia—Epirubicin—breast cancer	0.000232	0.00026	CcSEcCtD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—ABCC1—breast cancer	0.00023	0.00258	CbGpPWpGaD
Ceftazidime—Skin disorder—Epirubicin—breast cancer	0.00023	0.000258	CcSEcCtD
Ceftazidime—Paraesthesia—Methotrexate—breast cancer	0.000227	0.000255	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	0.000227	0.000254	CcSEcCtD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—ABCC1—breast cancer	0.000227	0.00253	CbGpPWpGaD
Ceftazidime—Dizziness—Capecitabine—breast cancer	0.000225	0.000252	CcSEcCtD
Ceftazidime—Vomiting—Docetaxel—breast cancer	0.000223	0.00025	CcSEcCtD
Ceftazidime—Rash—Docetaxel—breast cancer	0.000221	0.000248	CcSEcCtD
Ceftazidime—Hypotension—Epirubicin—breast cancer	0.000221	0.000248	CcSEcCtD
Ceftazidime—Dermatitis—Docetaxel—breast cancer	0.000221	0.000248	CcSEcCtD
Ceftazidime—Headache—Docetaxel—breast cancer	0.00022	0.000246	CcSEcCtD
Ceftazidime—Anaphylactic shock—Doxorubicin—breast cancer	0.000219	0.000245	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Methotrexate—breast cancer	0.000218	0.000245	CcSEcCtD
Ceftazidime—Pain—Methotrexate—breast cancer	0.000216	0.000242	CcSEcCtD
Ceftazidime—Vomiting—Capecitabine—breast cancer	0.000216	0.000242	CcSEcCtD
Ceftazidime—Nervous system disorder—Doxorubicin—breast cancer	0.000215	0.000241	CcSEcCtD
Ceftazidime—Thrombocytopenia—Doxorubicin—breast cancer	0.000214	0.00024	CcSEcCtD
Ceftazidime—Rash—Capecitabine—breast cancer	0.000214	0.00024	CcSEcCtD
Ceftazidime—Dermatitis—Capecitabine—breast cancer	0.000214	0.00024	CcSEcCtD
Ceftazidime—Headache—Capecitabine—breast cancer	0.000213	0.000239	CcSEcCtD
Ceftazidime—Skin disorder—Doxorubicin—breast cancer	0.000213	0.000238	CcSEcCtD
Ceftazidime—Paraesthesia—Epirubicin—breast cancer	0.000213	0.000238	CcSEcCtD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—TUBB3—breast cancer	0.000211	0.00236	CbGpPWpGaD
Ceftazidime—Nausea—Docetaxel—breast cancer	0.000208	0.000234	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Methotrexate—breast cancer	0.000207	0.000232	CcSEcCtD
Ceftazidime—Hypotension—Doxorubicin—breast cancer	0.000205	0.000229	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Epirubicin—breast cancer	0.000204	0.000229	CcSEcCtD
Ceftazidime—Pain—Epirubicin—breast cancer	0.000202	0.000227	CcSEcCtD
Ceftazidime—Nausea—Capecitabine—breast cancer	0.000202	0.000226	CcSEcCtD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—SLC39A6—breast cancer	0.000201	0.00225	CbGpPWpGaD
Ceftazidime—Urticaria—Methotrexate—breast cancer	0.000201	0.000225	CcSEcCtD
Ceftazidime—Abdominal pain—Methotrexate—breast cancer	0.0002	0.000224	CcSEcCtD
Ceftazidime—Body temperature increased—Methotrexate—breast cancer	0.0002	0.000224	CcSEcCtD
Ceftazidime—Paraesthesia—Doxorubicin—breast cancer	0.000197	0.00022	CcSEcCtD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—TUBB3—breast cancer	0.000196	0.00219	CbGpPWpGaD
Ceftazidime—Gastrointestinal pain—Epirubicin—breast cancer	0.000194	0.000217	CcSEcCtD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—TUBB3—breast cancer	0.000193	0.00215	CbGpPWpGaD
Ceftazidime—SLC22A6—SLC-mediated transmembrane transport—SLC5A5—breast cancer	0.000191	0.00214	CbGpPWpGaD
Ceftazidime—Gastrointestinal disorder—Doxorubicin—breast cancer	0.000189	0.000212	CcSEcCtD
Ceftazidime—Urticaria—Epirubicin—breast cancer	0.000188	0.000211	CcSEcCtD
Ceftazidime—Pain—Doxorubicin—breast cancer	0.000187	0.00021	CcSEcCtD
Ceftazidime—Abdominal pain—Epirubicin—breast cancer	0.000187	0.00021	CcSEcCtD
Ceftazidime—Body temperature increased—Epirubicin—breast cancer	0.000187	0.00021	CcSEcCtD
Ceftazidime—Hypersensitivity—Methotrexate—breast cancer	0.000186	0.000209	CcSEcCtD
Ceftazidime—SLC22A6—SLC-mediated transmembrane transport—SLC2A1—breast cancer	0.000184	0.00206	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—ATP7B—breast cancer	0.000184	0.00206	CbGpPWpGaD
Ceftazidime—Gastrointestinal pain—Doxorubicin—breast cancer	0.000179	0.000201	CcSEcCtD
Ceftazidime—Pruritus—Methotrexate—breast cancer	0.000179	0.000201	CcSEcCtD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—SLC2A2—breast cancer	0.000176	0.00196	CbGpPWpGaD
Ceftazidime—Hypersensitivity—Epirubicin—breast cancer	0.000174	0.000195	CcSEcCtD
Ceftazidime—Urticaria—Doxorubicin—breast cancer	0.000174	0.000195	CcSEcCtD
Ceftazidime—Abdominal pain—Doxorubicin—breast cancer	0.000173	0.000194	CcSEcCtD
Ceftazidime—Body temperature increased—Doxorubicin—breast cancer	0.000173	0.000194	CcSEcCtD
Ceftazidime—Diarrhoea—Methotrexate—breast cancer	0.000173	0.000194	CcSEcCtD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—ABCG2—breast cancer	0.000172	0.00192	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—ABCC1—breast cancer	0.000171	0.00191	CbGpPWpGaD
Ceftazidime—Pruritus—Epirubicin—breast cancer	0.000167	0.000188	CcSEcCtD
Ceftazidime—Dizziness—Methotrexate—breast cancer	0.000167	0.000187	CcSEcCtD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—SLC2A2—breast cancer	0.000163	0.00182	CbGpPWpGaD
Ceftazidime—Diarrhoea—Epirubicin—breast cancer	0.000162	0.000182	CcSEcCtD
Ceftazidime—Hypersensitivity—Doxorubicin—breast cancer	0.000161	0.000181	CcSEcCtD
Ceftazidime—Vomiting—Methotrexate—breast cancer	0.000161	0.00018	CcSEcCtD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—SLC2A2—breast cancer	0.00016	0.00179	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—ABCG2—breast cancer	0.00016	0.00179	CbGpPWpGaD
Ceftazidime—Rash—Methotrexate—breast cancer	0.000159	0.000179	CcSEcCtD
Ceftazidime—Dermatitis—Methotrexate—breast cancer	0.000159	0.000179	CcSEcCtD
Ceftazidime—Headache—Methotrexate—breast cancer	0.000158	0.000178	CcSEcCtD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—ABCG2—breast cancer	0.000157	0.00176	CbGpPWpGaD
Ceftazidime—Dizziness—Epirubicin—breast cancer	0.000156	0.000175	CcSEcCtD
Ceftazidime—Pruritus—Doxorubicin—breast cancer	0.000155	0.000174	CcSEcCtD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—TFRC—breast cancer	0.000153	0.00172	CbGpPWpGaD
Ceftazidime—Vomiting—Epirubicin—breast cancer	0.00015	0.000169	CcSEcCtD
Ceftazidime—Nausea—Methotrexate—breast cancer	0.00015	0.000168	CcSEcCtD
Ceftazidime—Diarrhoea—Doxorubicin—breast cancer	0.00015	0.000168	CcSEcCtD
Ceftazidime—Rash—Epirubicin—breast cancer	0.000149	0.000167	CcSEcCtD
Ceftazidime—Dermatitis—Epirubicin—breast cancer	0.000149	0.000167	CcSEcCtD
Ceftazidime—Headache—Epirubicin—breast cancer	0.000148	0.000166	CcSEcCtD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—NCOA2—breast cancer	0.000148	0.00165	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—TUBB3—breast cancer	0.000145	0.00163	CbGpPWpGaD
Ceftazidime—Dizziness—Doxorubicin—breast cancer	0.000145	0.000162	CcSEcCtD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—TFRC—breast cancer	0.000142	0.00159	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—SLC5A5—breast cancer	0.000141	0.00158	CbGpPWpGaD
Ceftazidime—Nausea—Epirubicin—breast cancer	0.000141	0.000158	CcSEcCtD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—TFRC—breast cancer	0.00014	0.00157	CbGpPWpGaD
Ceftazidime—Vomiting—Doxorubicin—breast cancer	0.000139	0.000156	CcSEcCtD
Ceftazidime—Rash—Doxorubicin—breast cancer	0.000138	0.000155	CcSEcCtD
Ceftazidime—Dermatitis—Doxorubicin—breast cancer	0.000138	0.000155	CcSEcCtD
Ceftazidime—Headache—Doxorubicin—breast cancer	0.000137	0.000154	CcSEcCtD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—NCOA2—breast cancer	0.000137	0.00153	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—SLC2A1—breast cancer	0.000136	0.00152	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—NCOA2—breast cancer	0.000135	0.00151	CbGpPWpGaD
Ceftazidime—SLC15A2—SLC-mediated transmembrane transport—ALB—breast cancer	0.000132	0.00148	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—SLC5A5—breast cancer	0.000131	0.00146	CbGpPWpGaD
Ceftazidime—Nausea—Doxorubicin—breast cancer	0.00013	0.000146	CcSEcCtD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—SLC5A5—breast cancer	0.000129	0.00144	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—SLC2A1—breast cancer	0.000126	0.00141	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—NCOA1—breast cancer	0.000124	0.00139	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—SLC2A1—breast cancer	0.000124	0.00139	CbGpPWpGaD
Ceftazidime—SLC15A1—SLC-mediated transmembrane transport—ALB—breast cancer	0.000123	0.00137	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—PLG—breast cancer	0.000121	0.00136	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—SLC2A2—breast cancer	0.000121	0.00135	CbGpPWpGaD
Ceftazidime—SLC22A5—SLC-mediated transmembrane transport—ALB—breast cancer	0.000121	0.00135	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—ABCG2—breast cancer	0.000119	0.00133	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—NCOA1—breast cancer	0.000115	0.00129	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—NCOA1—breast cancer	0.000114	0.00127	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—PLG—breast cancer	0.000113	0.00126	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—HMOX1—breast cancer	0.000112	0.00125	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—PLG—breast cancer	0.000111	0.00124	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—ABCB1—breast cancer	0.000107	0.0012	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—TFRC—breast cancer	0.000106	0.00118	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—HMOX1—breast cancer	0.000104	0.00116	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—HMOX1—breast cancer	0.000102	0.00114	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—NCOA2—breast cancer	0.000102	0.00114	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—ABCB1—breast cancer	9.97e-05	0.00111	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—ABCB1—breast cancer	9.8e-05	0.0011	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—SLC5A5—breast cancer	9.7e-05	0.00109	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—SLC2A1—breast cancer	9.37e-05	0.00105	CbGpPWpGaD
Ceftazidime—SLC22A6—SLC-mediated transmembrane transport—ALB—breast cancer	9.11e-05	0.00102	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—NCOA1—breast cancer	8.57e-05	0.000959	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—PLG—breast cancer	8.35e-05	0.000934	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—HMOX1—breast cancer	7.71e-05	0.000862	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—ABCB1—breast cancer	7.4e-05	0.000827	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—ALB—breast cancer	6.72e-05	0.000751	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—ALB—breast cancer	6.23e-05	0.000697	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—ALB—breast cancer	6.13e-05	0.000686	CbGpPWpGaD
Ceftazidime—SLC15A2—Transmembrane transport of small molecules—RAF1—breast cancer	6.08e-05	0.000679	CbGpPWpGaD
Ceftazidime—SLC15A1—Transmembrane transport of small molecules—RAF1—breast cancer	5.64e-05	0.000631	CbGpPWpGaD
Ceftazidime—SLC22A5—Transmembrane transport of small molecules—RAF1—breast cancer	5.55e-05	0.00062	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—ALB—breast cancer	4.63e-05	0.000518	CbGpPWpGaD
Ceftazidime—SLC22A6—Transmembrane transport of small molecules—RAF1—breast cancer	4.19e-05	0.000468	CbGpPWpGaD
